XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.2

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2025

Summary Of Significant Accounting Policies [Line Items]

Summary of Cash, Cash Equivalents and Restricted Cash

Cash as reported in the accompanying condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents and restricted cash as presented on the accompanying condensed consolidated balance sheets as follows:

		June 30, 2025				December 31, 2024
		(in thousands)
Cash and cash equivalents		$	748,953			$	681,101
Restricted cash — included in “Prepaid expenses and other current assets”			449				126
Restricted cash, non-current — included in “Other assets”			1,698				2,017
Total cash, cash equivalents and restricted cash		$	751,100			$	683,244

Summary of Other Current Liabilities

Other current liabilities presented on the condensed consolidated balance sheets consisted of the following balances:

		June 30, 2025				December 31, 2024
		(in thousands)
Accrued rebates and other related costs		$	19,065			$	210
Accrued interest			14,411				11,056
Accrued commercial liabilities			11,326				11,267
Accrued professional services			7,135				3,673
Deferred royalty obligations, current portion			4,812				144
Milestone liabilities			2,400				1,595
Income taxes payable			2,100				1,153
Other accrued liabilities			4,667				3,973
Total other current liabilities		$	65,916			$	33,071

Summary of Segment Information for Revenue, Significant Operating Expenses and Other Income (Expense), and Net Loss

The following table summarizes our segment information for significant operating expenses and includes a reconciliation to net loss:

		Three Months Ended June 30,								Six Months Ended June 30,
		2025				2024				2025				2024
		(in thousands)								(in thousands)
Revenues:
License and services revenue		$	37,440			$	2,168			$	117,130			$	213,288
Net product revenue			71,501				—				108,240				—
Royalty revenue			1,624				—				1,828				—
Total revenues, net			110,565				2,168				227,198				213,288
Operating costs and expenses:
Cost of revenues:
Cost of license, services and royalty revenue			805				598				1,410				1,196
Cost of goods sold			2,848				—				4,882				—
Total cost of revenues			3,653				598				6,292				1,196
Research and development by significant program:
Acoramidis for the treatment and primary prevention      of ATTR-CM			28,269				36,798				52,661				76,540
Infigratinib for achondroplasia and hypochondroplasia			30,191				22,098				58,125				43,283
BBP-418 for LGMD2I/R9			11,243				10,773				25,452				20,791
Encaleret for ADH1			13,128				10,608				28,587				23,152
Other development programs			10,536				9,693				21,966				41,977
Other research programs			17,864				24,725				35,871				49,924
Total segment research and development			111,231				114,695				222,662				255,667
Selling, general and administrative			129,154				59,523				235,519				125,330
Restructuring, impairment and related charges			805				2,891				1,375				6,291
Total operating costs and expenses			244,843				177,707				465,848				388,484
Loss from operations			(134,278	)			(175,539	)			(238,650	)			(175,196	)
Other income (expense), net:
Interest income			3,898				5,195				9,283				9,270
Interest expense			(37,637	)			(22,937	)			(79,778	)			(46,408	)
Gain on deconsolidation of a subsidiary			—				126,294				—				126,294
Losses on extinguishments of debt			—				—				(21,155	)			(26,590	)
Net loss from equity method investments			(20,189	)			(7,925	)			(35,745	)			(7,925	)
Other income (expense), net			6,548				(632	)			14,779				8,851
Total other income (expense), net			(47,380	)			99,995				(112,616	)			63,492
Loss before income taxes			(181,658	)			(75,544	)			(351,266	)			(111,704	)
Income tax expense			2,100				—				2,100				—
Net loss			(183,758	)			(75,544	)			(353,366	)			(111,704	)
Net loss attributable to redeemable convertible    noncontrolling interests and noncontrolling interests			1,855				2,088				4,041				3,032
Segment net loss attributable to common stockholders    of BridgeBio		$	(181,903	)		$	(73,456	)		$	(349,325	)		$	(108,672	)

Schedule of Inventories Presented on Condensed Consolidated Balance Sheet

Inventories presented on the condensed consolidated balance sheet as of June 30, 2025 consisted of the following balances:

		June 30, 2025
		(in thousands)
Raw materials		$	11,463
Work in progress			1,065
Finished goods			5,749
Total inventories		$	18,277

Customer Concentration Risk

Summary Of Significant Accounting Policies [Line Items]

Schedule of Concentration, Percentage of Gross Revenues

The following table summarizes customers that represent 10% or greater of our consolidated total gross revenues:

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Bayer (as described in Note 11)	*		16.7%		30.1%		61.4%
Kyowa Kirin Co., Ltd	*		66.2%		*		33.8%
Alexion (as described in Note 11)	22.3%		14.7%		12.0%		*
Customer A	19.4%		*		15.2%		*
Customer B	17.5%		*		13.7%		*
Customer C	13.3%		*		*		*
Customer D	12.2%		*		10.1%		*

* Represents less than 10% and/or not a customer in the applicable period.

Geographical Risk

Summary Of Significant Accounting Policies [Line Items]

Schedule of Concentration, Percentage of Gross Revenues

Total revenues, net is attributed to regions based on the location of our customers or partners.

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
U.S.	64.7%		17.2%		47.7%		4.8%
Europe, Middle East, and Africa (EMEA)	31.7%		16.7%		49.4%		61.4%
Asia-Pacific (APAC)	3.6%		66.1%		2.9%		33.8%
	100.0%		100.0%		100.0%		100.0%

X

- Definition

Schedule of cash, cash equivalents and restricted cash.

+ References

No definition available.

+ Details

Name:	bbio_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock
Namespace Prefix:	bbio_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Summary of significant accounting policies.

+ References

No definition available.

+ Details

Name:	bbio_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix:	bbio_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of other current liabilities.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCurrentLiabilitiesTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483489/210-10-50-1

+ Details

Name:	us-gaap_ScheduleOfInventoryCurrentTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: